Literature DB >> 9252194

Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy.

C Meijer1, E G de Vries, W A Dam, M H Wilkinson, H Hollema, H J Hoekstra, N H Mulder.   

Abstract

To detect low-level DNA platination, a sensitive immunocyto- and histochemical technique was developed using a polyclonal antibody. The antibody GPt, derived after immunization of rabbits with highly platinated DNA and purified with affinity chromatography, detected the main platinum (Pt)-containing intrastrand and interstrand adducts. Double-fluorescence microscopy image analysis was used to quantify Pt-DNA adducts with Hoechst 33258 fluorescence to locate the nuclei and with fluorescein isothiocyanate fluorescence to measure the immunosignal. A two- to five-fold dose-dependent difference in the level of cisplatin (CDDP)-induced Pt-DNA adducts between a CDDP-sensitive and -resistant human tumour cell line was detected. Large differences in Pt-DNA adduct levels after in vitro CDDP incubation between human buccal cells, lymphocytes and biopsies of different tumour types were observed. Pt-DNA adduct levels were fivefold higher in human testicular tumours than in colon tumours, representing CDDP-sensitive and -resistant tumours, respectively, in the clinic. These data suggest the possibility of predictive testing by measuring Pt-DNA adduct levels. Pt-DNA adducts in patients after treatment with CDDP were shown in normal buccal cells and in imprints of fresh tumour biopsies as well as in paraffin-embedded tumour cells. The analysis of Pt-DNA adducts at a single-cell level in small samples of normal and tumour cells during and/or after treatment is feasible with GPt and will hopefully enable more selective treatment of patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252194      PMCID: PMC2224054          DOI: 10.1038/bjc.1997.381

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

Review 1.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.

Authors:  P A Andrews; S B Howell
Journal:  Cancer Cells       Date:  1990-02

2.  Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.

Authors:  M J Tilby; C Johnson; R J Knox; J Cordell; J J Roberts; C J Dean
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

3.  Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.

Authors:  R J Parker; I Gill; R Tarone; J A Vionnet; S Grunberg; F M Muggia; E Reed
Journal:  Carcinogenesis       Date:  1991-07       Impact factor: 4.944

4.  Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum--DNA adducts.

Authors:  I Gill; F M Muggia; P M Terheggen; C Michael; R J Parker; V Kortes; S Grunberg; M C Christian; E Reed; L den Engelse
Journal:  Ann Oncol       Date:  1991-02       Impact factor: 32.976

5.  Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.

Authors:  R Pieters; D R Huismans; A H Loonen; K Hählen; A van der Does-van den Berg; E R van Wering; A J Veerman
Journal:  Lancet       Date:  1991-08-17       Impact factor: 79.321

6.  Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.

Authors:  A M Fichtinger-Schepman; S D van der Velde-Visser; H C van Dijk-Knijnenburg; A T van Oosterom; R A Baan; F Berends
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

7.  A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance.

Authors:  G A Hospers; C Meijer; L de Leij; D R Uges; N H Mulder; E G de Vries
Journal:  Int J Cancer       Date:  1990-07-15       Impact factor: 7.396

8.  Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.

Authors:  P M Terheggen; B G Floot; E L Lempers; O van Tellingen; A C Begg; L den Engelse
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  A novel dye exclusion method for testing in vitro chemosensitivity of human tumors.

Authors:  L M Weisenthal; J A Marsden; P L Dill; C K Macaluso
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

10.  The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.

Authors:  C Meijer; N H Mulder; G A Hospers; D R Uges; E G de Vries
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

View more
  5 in total

Review 1.  Cytometric assessment of DNA damage in relation to cell cycle phase and apoptosis.

Authors:  Xuan Huang; H Dorota Halicka; Frank Traganos; Toshiki Tanaka; Akira Kurose; Zbigniew Darzynkiewicz
Journal:  Cell Prolif       Date:  2005-08       Impact factor: 6.831

Review 2.  Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

Authors:  George D Cimino; Chong-xian Pan; Paul T Henderson
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

3.  Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.

Authors:  Bernd Liedert; Dick Pluim; Jan Schellens; Jürgen Thomale
Journal:  Nucleic Acids Res       Date:  2006-03-29       Impact factor: 16.971

4.  Immunodetection of human topoisomerase I-DNA covalent complexes.

Authors:  Anand G Patel; Karen S Flatten; Kevin L Peterson; Thomas G Beito; Paula A Schneider; Angela L Perkins; Daniel A Harki; Scott H Kaufmann
Journal:  Nucleic Acids Res       Date:  2016-02-24       Impact factor: 16.971

5.  DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.

Authors:  Alessia Stornetta; Maike Zimmermann; George D Cimino; Paul T Henderson; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2017-01-03       Impact factor: 3.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.